Brought to you by 
Resolve and Takeda work together to develop nuclease proteins for lupus
28 Mar 2013
Executive Summary
Resolve Therapeutics LLC (targeted biologics for lupus) has found its first major pharma partner through a new deal with Takeda Pharmaceutical Co. Ltd. The companies will further develop Resolve’s preclinical lupus candidate RSLV132, with Takeda retaining an exclusive option for global rights to the agent and all other compounds in the start-up’s pipeline.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Resolve and Takeda work together to develop nuclease proteins for lupus
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice